Aurobindo Q3 profit seen up 38%, US biz may support revenue

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Aurobindo Pharma's third quarter profit is seen rising 37.8 percent year-on-year to Rs 530 crore and revenue may increase 14.8 percent to Rs 3,636 crore, according to average of estimates of analysts polled by CNBC-TV18.

Operating profit (earnings before interest, tax, depreciation and amortisation) in Q3 is likely to jump 40 percent to Rs 857 crore and margin may expand 430 basis points to 23.6 percent compared to year-ago period.

Revenue growth may be led by traction in US business. Sales of Abilify, Suprax, injectibles and recent ANDA approvals may aid US business that could even grow 30-40 percent YoY.

Europe & Rest of the World could be subdued due to currency depreciation and low growth in Europe. API business is likely to grow 5-7 percent YoY.